Thyroid B-flow twinkling sign: a new feature of papillary cancer by Brunese, Luca et al.
CLINICAL STUDY
Thyroid B-ﬂow twinkling sign: a new feature of papillary cancer
Luca Brunese, Antonio Romeo
1, Sergio Iorio
2, Giuseppina Napolitano
1, Stefano Fucili
1, Pio Zeppa
3,
Gianfranco Vallone
1, Gaetano Lombardi
4, Antonio Bellastella
2, Bernadette Biondi
4 and Antonio Sodano
1
Department of Health Science, Chair of Radiology, University of Molise, Campobasso, Italy,
1Department of Radiology, University of Naples ‘Federico II’,
Policlinico Universitario Federico II, Via Pansini 5, 80131 Naples, Italy,
2Department of Clinical and Experimental Medicine and Surgery ‘F. Magrassi’,
A. Lanzara’, Second University of Naples, Naples, Italy,
3Department of Anatomic Pathology and Cytopathology and
4Departments of Molecular and
Clinical Endocrinology and Oncology, University of Naples ‘Federico II’, Naples, Italy
(Correspondence should be addressed to A Sodano; Email: ansodano@unina.it)
Abstract
Background: Microcalciﬁcations (aggregated with psammoma bodies), detected by ultrasound (US), are
the most speciﬁc feature of papillary thyroid cancer (PTC). Using B-ﬂow imaging (BFI), we identiﬁed a
new sign (the twinkling sign; BFI-TS) in ‘suspect’ PTC nodules, which appeared to be generated by
microcalciﬁcations.
Objective: To evaluate whether the BFI-TS was predictive of malignancy, we correlated the BFI-TS with
the results of ﬁne needle aspiration cytology and histology.
Design: Cross-sectional cohort study from September 2006 to April 2008.
Setting: Department of Radiology and Endocrinology, University of Naples Federico II, and Department
of Endocrinology, Second University of Naples.
Patients: A total of 306 consecutive patients with 539 thyroid nodules O8 mm in diameter.
Main outcome measure: US and BFI examinations were performed with the Logiq 9 system (General
Electric Company, Milan, Italy); all patients underwent cytological examination.
Results: Cytology revealed 455 (84.4%) benign nodules and 84 (15.6%) malignant nodules; the latter
were conﬁrmed by postsurgical histological examination (76 cases of PTC, 7 follicular carcinoma, and
1H u ¨rthle cell carcinoma). All suspect nodules, namely, nodules with potential predictors of thyroid
malignancy (e.g., microcalciﬁcations and intra-nodal vascularity), were analyzed by cytology or
histology (or both). Of 84, 68 (80.9%) of malignant nodules had R4 or more BFI-TSs in at least one
scan versus only 12 of 455 (2.6%) of benign lesions.
Conclusions: Our results indicate that the BFI-TS could be a reliable diagnostic technique in the
management of suspect thyroid nodules.
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Introduction
Thyroidnodulardiseaseisverycommon.Dependingonthe
method of evaluation, the prevalenceof thyroidnodules in
thegeneralpopulationis20–50%(1,2).Theprevalenceof
malignant nodules is 5–15% (1, 3–7) depending on age,
gender, radiation exposure, and family history (1).
Papillarythyroidcancer(PTC)isthemostfrequentthyroid
carcinoma(80%).Itsannualincidencevariesconsiderably,
namely from 1.2 to 2.6 cases per 100 000 individuals in
men and 2.0 to 3.8 cases per 100 000 in women (8, 9).
The incidence of PTC has increased by more than 5% per
year in the last decade (10, 11).
Ultrasound(US)isthemorphologicalimagingmodality
of choice for the study of thyroid nodules. US-guided ﬁne
needle aspiration (FNA) is the gold standard for diagnosis
and itisparticularly importantinthe assessmentofsmall
or non-palpable nodules (12, 13).
A consensus conference on several US characte-
ristics potentially predictive of thyroid malignancy
(microcalciﬁcations, hypoechogenicity, irregular
margins, absence of a halo, predominantly solid
composition, intra-nodal vascularity, and regional
lymphadenopathy) concluded that calciﬁcations within
the nodule increase the likelihood of malignancy (14).
In particular, microcalciﬁcations in a predominantly
solid nodule are associated with an approximately
threefold higher cancer risk whereas coarse calciﬁca-
tions are associated with a twofold increased risk,
compared with predominantly solid nodules (14).
B-ﬂowimaging(BFI)isanon-Dopplertechniquewidely
usedtoevaluatecarotidarterystenosisandothervascular
diseases (15, 16). While evaluating the application of BFI
for studies of nodular vascularization, we serendipitously
identiﬁed a new sign (the ‘twinkling sign’; BFI-TS) in
‘suspect’PTCnodules,whichappearedtobegeneratedby
microcalciﬁcations.Thissignresembles the color Doppler
TSgeneratedby renal stones(17). The BFI-TSisa rapidly
ﬂashing white light behind such stationary objects as
microcalciﬁcations, which gives the appearance of
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impinges a rough interface composed of sparse reﬂectors,
the signisgeneratedby the phase shift,therebycausinga
faint variation of the sonographic beam at the interface.
The sign is also caused by the increase of pulse duration,
which results in multiple reﬂections in the medium.
Thyroid microcalciﬁcations increase in size by aggregat-
ing with primary psammoma bodies (PBs); they consist
mainly of highly reﬂecting crystalline aggregates of
calcium (18).
The aim of this study was to determine whether the
BFI-TS is predictive of malignancy. To this aim, we
investigated whether the sign was correlated with
microcalciﬁcations of thyroid nodules and the results
of US-guided FNA.
Materials and methods
Patients
From a sample of 2686 patients from the Campania
Region(Naplesmetropolitanarea),amildiodine-deﬁcient
region (19), referred to the Department of Radiology and
Endocrinology,UniversityofNaplesFedericoII,andtothe
Department of Endocrinology, Second University of
Naples, between September 2006 and April 2008, we
enrolled306subjectsbasedontheselectioncriteriaofthe
2005 US Consensus Conference Statement of Society of
Radiologists (14),i.e.,thesepatientswereaffectedbysolid
thyroid lesions larger than 8 mm and had normal serum
levels of thyroid hormone, thyroid-stimulating hormone,
andcalcitonin.These306consecutivepatients(agerange
19–74 years, mean age 42.2G9.3 years; 98 males and
208 females) had 539 palpable and non-palpable solid
thyroid nodules. All 539 nodules had the following US
characteristics of potential predictors of thyroid malig-
nancy: hypoechogenicity, irregular margins, absence of a
halo, microcalciﬁcations, solid composition, and intra-
nodular vascularity.
The study was conducted according to the principles
of the Declaration of Helsinki. Written informed consent
was obtained from all subjects. The study was approved
by the ethics committee of the University of Molise.
Methods
US and BFI US examinations were performed with the
GE Logiq 9 machine (General Electric Company), a
commercially available real-time US system, equipped
with a 9–14 and 6–8 MHz linear array transducer. All
examinations were performed separately by two radiol-
ogists, and data analysis was performed by another
investigator. The following US characteristics were
recorded for each nodule: size, parenchymal compo-
sition, echogenicity, presence or absence of halo, margin
appearance, and presence or absence of microcalciﬁca-
tions. The size was recorded as three orthogonal
dimensions. The echogenicity of each nodule was
determined bycomparing the solid portion of the nodule
to the surrounding thyroid parenchyma and designated
‘hyperechoic’ when it was more echogenic, ‘isoechoic’
when it was similar, and ‘hypoechoic’ when it was less
echogenic than the thyroid tissue (3). The presence of
hyperechoic spots (calciﬁcations or colloidal crystals)
was evaluated in relation to the surrounding thyroid
tissue (20, 21).
BFI was performed at 10 MHz (M12L) and 7 MHz
(7L) with the BFI capability at the level of the nodule.
The pulse repetition index was set at 3. BFI gain was not
ﬁxed and was adjusted to allow a better visualization of
the signs.
We examined the BFI images for the presence,
appearance, and intensity of TSs. For each nodule, we
recorded the maximum number of well-differentiated
signals per scan; we excluded scans in which TSs were
less than 2 mm apart in a single scan. Each US
examination took 15G4.3 min, whereas it took only
5 min to identify the thyroid BFI-TS.
After US features were assessed, a cytological
examination was carried out and the ﬁndings were
recorded by a radiologist. FNA was performed by the
endocrinologist under the US guidance of the radiolo-
gist. Physicians were highly trained in the technique of
US-guided FNA with 27 and 22 gauge needles,
according to the procedure described elsewhere (22,
23). Three or four smears were prepared; the ﬁrst was
air dried and immediately stained with Diff-Quik stain,
which is a May-Grunwald–Giemsa modiﬁed stain in
which smears are stained in less than 1 min. The other
smears were ﬁxed in absolute alcohol for subsequent
AbTPO smear or immunostaining. Diff-Quik smears
were immediately evaluated by a cytopathologist who
assessed the adequacy of the samples; the FNA was
repeated in case of inadequate or scarcely cellulated
smears. Cases classiﬁed ‘benign’ from cytology were
scheduled for a clinical and US follow-up to monitor the
size and US features of the nodules. Patients with
suspect or malignant cytological features underwent
surgery during which intra-surgical frozen sections
were examined to verify diagnosis. If the cytological
analysis was negative, the patient was re-examined at 3
and 6 months to monitor changes in nodule size. We
used cytospray ﬁxation of frozen intra-operative sec-
tions to optimize the reading of frozen intra-operative
sections (24) and to compare cytological imprints.
Lastly, the c
2 test and the predictivity test were used for
statistical analysis.
Results
Cytology and histology
The cytology specimens of 171 of 539 nodules (31.7%)
were not evaluable; thus FNA was repeated 1 month
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nodules (84.4%), 11 suspect nodules (2%), and 73
malignant nodules (13.6%). The 84 patients with
suspect or malignant nodules underwent surgery, and
histology showed PTC in 76 (90.5%) cases, follicular
thyroid carcinoma (FTC) in 7 (8.3%) cases, and Hu ¨rthle
cell carcinoma (HCC) in 1 (1.2%) case. The prevalence
of cancer was 39% in nodules measuring between 9 and
15 mm and 61% in nodules larger than 15 mm.
Conventional US and color Doppler ﬂow
sonography
Table 1 shows the conventional sonographic features of
thyroid cancer as well as the new BFI-TS identiﬁed in
our patients together with their speciﬁcity, sensitivity,
and predictive value for malignancy.
BFI evaluation
The BFI-TS was identiﬁed in 147 of the 539 nodules
(26.3%; inter-observer variation: 4.32G2.18%). As
shown in Table 1, 4 PTCs had between 1 and 3 BFI-TSs
per scan, and 68 PTCs had 4 or more BFI-TSs per scan
separated by more than 2 mm. Of the 67 nodules with
less than 3 signs/scan, 4 (6%) were PTC and 63 (94%)
were benign. Of the 80 nodules with 4 or more
signs/scan, 68 (85%) were PTC and 12 (15%) were
benign. The BFI-TS was not found in non-PTC tumors
(FTC or HCC).
The speciﬁcity and sensitivity of the BFI-TS for all
thyroid cancers with R4 or more signs were 97.4
and 80.9% respectively (Table 1). These values are
signiﬁcantly higher than the values we obtained for
conventional US features of thyroid malignancy (micro-
calciﬁcations: speciﬁcity 92.3% and sensitivity 41.7%;
hypoechogenicity: speciﬁcity 40.9% and sensitivity
72.6%). They are also signiﬁcantly higher (X
2Z337.13;
P!0.0001) than the values previously reported for the
conventional US features (14). The sensitivity of the
BFI-TS was even greater when we considered only PTC
(89.5 vs 80.9% for non-PTC tumors).
Discussion
The early diagnosis of PTC reduces the incidence of
metastatic lesions and increases 5-year survival (96%)
(14). It is generally agreed that ﬁne punctuate
calciﬁcations on US are the most reliable indicators of
malignancy because they correspond to PBs on
microscopic examination. PBs are concentric laminated
calciﬁed structures most commonly found in neoplasms
such as meningiomas, papillary carcinoma of the ovary,
and PTC (25, 26). The coalescence of various PBs
results in larger calciﬁcations (26, 27). The aim of this
study was to evaluate the diagnostic value of the BFI-TS
in visualizing microcalciﬁcations generated by PB
aggregation in solid thyroid nodules.
In our study, the BFI-TS was unrelated to intra-
nodular vascularization on computational ﬂow
dynamics, but was detected only at the site of
microcalciﬁcations. It is feasible that the signal resulted
from an aggregation of PBs. Our histological data are in
line with this concept (see Figs 1D and 2D).
Wealsoexaminedthesensitivity,speciﬁcity,andpositive
predictive values of conventional US features associated
with an increased risk of thyroid cancer (microcalciﬁca-
tions, hypoechogenicity, irregular margins, absence of a
halo, and intra-nodular vascularity). Our results are in
agreement with a previous study on conventional US
features in which microcalciﬁcations had the highest
positive predictive value and speciﬁcity for malignancy
(24.3–70.7% and 85.8–95.0% respectively) (14).
We found that the BFI-TS identiﬁed signiﬁcantly more
microcalciﬁcations than B-mode US. In fact, based on
the BFI-TS with 4 or more signs/scan, 80 thyroid
nodules were positive versus 66 identiﬁed by B-mode US
(Fig. 1). In addition, of the 80 BFI-TS-positive lesions,
Table 1 Ultrasound features associated with thyroid cancer in the 539 nodules examined.
US features
Papillary
cancer
Non-papillary
cancer Benign Signiﬁcance
Speciﬁcity
(%)
Sensitivity
(%) PPV (%) NPV (%)
Irregular margins or no halo 38/76 5/8 155/455 X
2Z8.95 65.9 51.2 21.7 88
PZ0.003
Microcalciﬁcations 31/76 4/8 35/455 X
2Z72.43 92.3 41.7 50 89.5
P!0.0001
Hypoechogenicity 55/76 6/8 269/455 X
2Z5.44 40.9 72.6 18.5 89
PZ0.02
CDF intra-nodular 46/76 7/8 93/455 X
2Z65.33 79.6 63.1 36.3 92.1
P!0.0001
No BFI-TS 5/76 8/8 380/455 X
2Z166.21 16.5 15.5 3.3 51.4
P!0.0001
1–3 BFI-TSs 4/76 0/8 63/455 X
2Z5.38 86.1 4.8 6 83
PZ0.02
R4 BFI-TSs 68/76 0/8 12/455 X
2Z337.13 97.4 80.9 85 96.5
P!0.0001
US, ultrasound; PPV, positive predictive value; NPV, negative predictive value; CDF, color Doppler ﬂow; BFI, B-ﬂow imaging; TS, twinkling sign.
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85%, all PTC) and 12 were benign (12 of 80, 15%). Of
the 66 cases of microcalciﬁcations identiﬁed with
B-mode US, 31 were PTC and 35 were benign lesions.
Thirty-seven microcalciﬁcation-associated PTCs were
detected only by the BFI-TS; B-mode US failed to identify
these cases (Fig. 2). Consequently, BFI-TS is more
sensitive than B-mode US in detecting PBs (sensitivity:
80.9 vs 41.7%).
The BFI-TS was more frequent in PTC than in other
thyroid lesions. Moreover, the speciﬁcity, sensitivity, and
positive predictive value of R4 or more BFI-TS/scan for
PTC were higher than those of the conventional US
features (Table 1). Our study indicates that nodules with
at least 4 signs per scan are highly suggestive of
malignancy. This assessment, based on statistical
criteria, is supported by the histological observation,
within PTCs of PBs.
Figure 1 Ultrasound B-mode of a suspect
thyroid nodule. (a) Transverse US image of
a nodule containing multiple ﬁne echogeni-
cities (arrow) with no comet-tail artifact.
(b)AdditionofcolorDopplermodeshowsﬂow
within the mural component. (c) Transverse
B-ﬂow image of a nodule containing multiple
twinkling signs, highly suggestive of malig-
nancy. Fine needle aspiration and surgery
conﬁrmed papillary carcinoma. (d) Histo-
logical image showing a papillary cancer and
psammoma body (arrow).
Figure 2 Mode and color Doppler of a non-
suspect thyroid nodule. (a) Sagittal image of
a solid nodule suggesting a benign lesion.
(b) Addition of color Doppler mode did not
showmarkedinternalvascularity. (c) Sagittal
B-ﬂow image of a nodule containing multiple
twinkling signs, suggesting malignancy. Fine
needle aspiration and surgery conﬁrmed
papillary carcinoma. (d) Histological image
showing a papillary cancer and psammoma
body (arrow).
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appositions of calcium salts and other minerals (see
Fig. 2D). It is likely that the lamellar layer morphologyof
PBs determines a number of calcium interfaces that
produce the twinkling phenomenon. It is conceivable
that studies of BFI-TS features in benign and malignant
lesions might reveal differences between lesions that
produce large amounts of PBs PTC and lesions that
produce lower amounts, or that produce microcalciﬁca-
tions with physical characteristics different from PBs.
Thus far, the BFI technique has been used to study the
vascular circulation mainly in the carotid artery. Our
results indicate that this technique can be applied to the
studies of thyroid nodules, and that its sensitivity and
speciﬁcity is higher than those of traditional US
diagnostic techniques. However, longitudinal studies
on a large population are required to verify the efﬁcacy
of BFI in the diagnosis of thyroid carcinoma.
Lastly, the GE Logiq 9 BFI apparatus was not designed
to visualize the TS but to study vascularization. One
may envisage the development of software that
enhances the TS to a point where it reveals PBs as
small as 10–100 mm, thereby increasing the early
detection rate of PTCs.
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